A phase I trial of cisplatin in hypertonic saline and escalating doses of 5‐fluorouracil by continuous intravenous infusion in patients with advanced malignancies Journal Article


Authors: Saltz, L.; Kelsen, D.
Article Title: A phase I trial of cisplatin in hypertonic saline and escalating doses of 5‐fluorouracil by continuous intravenous infusion in patients with advanced malignancies
Abstract: Thirty‐four patients with incurable solid tumors were treated in a Phase I trial with a fixed dose of high‐dose cisplatin (CDDP) administered in hypertonic saline and escalating doses of infusional 5‐fluorouracil (5‐FU). Five treatment levels of 5‐FU, ranging from 500 to 900 mg/m2/day for 5 days, were studied. Leukopenia, thrombocytopenia, and oral mucositis were the dose‐limiting toxicities encountered. Nephrotoxicity was minimal. Ototoxicity and peripheral neuropathies were rare and mild in this patient group, but most patients received only a small number of treatment cycles. Diarrhea was not dose‐limiting. Two complete responses (one non‐small cell lung cancer and one sweat gland carcinoma) were observed. No other major responses were noted. With the dose of CDDP set at 35 mg/m2/day for 5 consecutive days, the maximum tolerated dose (MTD) of a concurrent 5‐day 5‐FU infusion was found to be 900 mg/m2/day. The recommended dosages for Phase II trials are 35 mg/m2/day CDDP and 800 mg/m2/day 5‐FU for 5 consecutive days. Cancers of the lung, breast, gastrointestinal tract, and genitourinary tract would be reasonable targets for Phase II studies. Copyright © 1990 American Cancer Society
Keywords: adult; cancer chemotherapy; clinical article; aged; carcinoma, squamous cell; cisplatin; fluorouracil; advanced cancer; side effect; adenocarcinoma; leukopenia; thrombocytopenia; antineoplastic combined chemotherapy protocols; peripheral neuropathy; dose-response relationship, drug; phase 1 clinical trial; intravenous drug administration; ototoxicity; middle age; drug evaluation; human; male; female; priority journal; article; support, u.s. gov't, p.h.s.; saline solution, hypertonic
Journal Title: Cancer
Volume: 66
Issue: 8
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 1990-10-15
Start Page: 1688
End Page: 1691
Language: English
DOI: 10.1002/1097-0142(19901015)66:8<1688::Aid-cncr2820660806>3.0.Co;2-k
PUBMED: 2208023
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 27 January 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Leonard B Saltz
    790 Saltz
  2. David P Kelsen
    537 Kelsen